Gallant Reports Positive Pilot Data for Feline Osteoarthritis Stem Cell Therapy; Receives FDA Eligibility for Expanded Conditional Approval Pathway

Randomized, placebo-controlled study shows over 76% of treated cats demonstrated improved quality of life SAN DIEGO, April 15, 2026 /PRNewswire/ -- Gallant, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced positive results from...